What Happened
India is on the cusp of having its first indigenously developed dengue vaccine, as Panacea Biotec's candidate vaccine — DengiAll — has entered final Phase III clinical trials. Over 10,000 volunteers across India are enrolled in the study, which is overseen by the Indian Council of Medical Research (ICMR). If the trial results are favourable, the vaccine could be ready for rollout as early as 2027.
The development is particularly significant because dengue is one of the most pervasive mosquito-borne viral diseases in India, with the country accounting for nearly one-third of the global dengue disease burden. The study is the culmination of nearly 15 years of R&D by Panacea Biotec.
Globally, dengue affects 100–400 million people annually. In India alone, an estimated 28 million dengue cases and nearly 20,000 related deaths were recorded in 2019 — far higher than officially reported figures due to chronic underreporting. An affordable, Indian-made vaccine is seen as critical to making dengue immunisation accessible across lower-income countries in the tropical belt.
Static Topic Bridges
1. Dengue Fever — Disease Profile, Transmission, and Epidemiology
Dengue is an acute viral illness caused by dengue virus (DENV), a flavivirus with four distinct serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Infection with one serotype confers lifetime immunity to that serotype but only partial and temporary protection against the others. A second infection by a different serotype dramatically increases the risk of Dengue Haemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) — the severe, potentially fatal forms of the disease.
Transmission: - Vector: Female Aedes aegypti mosquito (primary); Aedes albopictus (secondary) - Aedes aegypti is a daytime biter and breeds in clean, stagnant water (tyres, coolers, flower pots, water tanks) - There is no direct person-to-person transmission — the virus requires the mosquito as an intermediate host
India's dengue burden: - India accounts for approximately one-third of global dengue disease burden - Dengue cases quadrupled from 2015 to 2020 (National Centre for Vector Borne Diseases Control data) - The monsoon season (July–October) is peak dengue season, as standing water provides breeding grounds - Urban and peri-urban areas are worst affected due to water storage practices and densely packed housing - Major affected states: Maharashtra, Karnataka, Tamil Nadu, Uttar Pradesh, Rajasthan
The four-serotype challenge: The existence of four serotypes makes vaccine development uniquely difficult — a vaccine must protect against all four simultaneously, and partial protection can paradoxically worsen disease (antibody-dependent enhancement).
2. Dengue Vaccine Development — Global and Indian Context
The only globally approved dengue vaccine is Dengvaxia (CYD-TDV) by Sanofi Pasteur. However, Dengvaxia has serious limitations: - Approved only for individuals aged 9–45 who have had at least one prior dengue infection (confirmed seropositive) - In seronegative individuals (no prior infection), Dengvaxia can increase the severity of dengue — this led to a major public health controversy in the Philippines (2017–2019) where thousands of children were vaccinated without prior serostatus screening - High cost makes it inaccessible in low-income countries
DengiAll by Panacea Biotec: - Tetravalent live-attenuated dengue vaccine (targeting all four serotypes) - Phase III trial: 10,000+ volunteers across India, ICMR oversight - If approved, would be the first Indian-made dengue vaccine - Expected rollout: 2027 (if trial results favourable) - Key advantage: Indian manufacturing = lower cost, suited for mass rollout in LMICs
Other global candidates in pipeline: - TAK-003 (Qdenga) by Takeda: Approved in the EU (2022) and Indonesia; Phase III trials in India initiated - V180 (US NIH candidate): In early-stage trials - Serum Institute of India: MoU with DNDi for monoclonal antibody dengue treatment (not vaccine)
3. India's Vaccine Development Ecosystem — From Discovery to Deployment
India is known as the "pharmacy of the world," supplying over 60% of global vaccine doses. The dengue vaccine trial reflects India's growing indigenous vaccine R&D capacity.
Key institutions: - ICMR (Indian Council of Medical Research): Primary national medical research body; oversees clinical trials for national disease priorities - DBT (Department of Biotechnology): Funds vaccine R&D through Biotechnology Industry Research Assistance Council (BIRAC) - CDSCO (Central Drugs Standard Control Organisation): Drugs regulator; approves new vaccines after trial data review - National Regulatory Authority (NRA): India's vaccine regulatory system was assessed by WHO as "functional" — enabling expedited WHO prequalification for Indian vaccines
Clinical trial phases: - Phase I: Safety in small group (20–100 people) - Phase II: Safety + immunogenicity in larger group (hundreds) - Phase III: Efficacy, safety, dosage in large population (thousands to tens of thousands) — this is where DengiAll currently stands - Phase IV: Post-market surveillance
Mission Indradhanush and Vector-Borne Diseases: India's immunisation infrastructure (Universal Immunisation Programme — UIP) can be leveraged for dengue vaccine rollout. The National Vector Borne Disease Control Programme (NVBDCP) under MoHFW coordinates dengue surveillance and control.
4. One Health Approach — Dengue, Climate, and Urbanisation
Dengue is increasingly understood through a "One Health" lens — integrating human health, animal/vector biology, and environmental factors.
Climate change and dengue spread: - Rising temperatures and altered rainfall patterns expand the geographic range of Aedes mosquitoes - Studies project dengue will spread to previously non-endemic regions in Europe and North America by 2050 under current warming trajectories - In India, climate variability is extending the dengue season beyond the traditional monsoon window
Urban health policy implications: - Integrated Vector Management (IVM): combines larval source reduction, biological controls (e.g., Bacillus thuringiensis israelensis — Bti), and targeted insecticide spraying - Singapore's dengue control model (rigorous surveillance + community engagement) is often cited as best practice - The Wolbachia-infected Aedes aegypti approach: Mosquitoes carrying Wolbachia bacteria cannot efficiently transmit dengue; field trials in several countries show 77% reduction in dengue incidence
Key Facts & Data
- Dengue causative agent: Dengue virus (DENV), 4 serotypes (DENV 1–4), Flaviviridae family
- Vector: Aedes aegypti (primary), Aedes albopictus (secondary)
- Global burden: 100–400 million infections per year
- India's share: ~1/3 of global dengue burden; 28 million estimated cases and ~20,000 deaths in 2019
- DengiAll (Panacea Biotec): Tetravalent live-attenuated vaccine; Phase III trials with 10,000+ volunteers under ICMR oversight
- Panacea Biotec R&D timeline: ~15 years of development
- Projected rollout: 2027 if Phase III results favourable
- Only approved dengue vaccine globally: Dengvaxia (Sanofi) — restricted to seropositive individuals aged 9–45
- Takeda's TAK-003 (Qdenga): Approved in EU (2022); Phase III initiated in India
- NVBDCP: National Vector Borne Disease Control Programme — nodal body under MoHFW
- UIP: Universal Immunisation Programme — existing infrastructure for potential dengue vaccine rollout
- Antibody-Dependent Enhancement (ADE): Key immunological challenge in dengue vaccine design; second infection by different serotype can worsen disease